Holen Sie sich die Stockscreener-App
5.87
0.17%
-0.010
Vorhandelsmarkt:
5.93
0.06
+1.02%
Rezolute Inc Aktie (RZLT) Neueste Nachrichten
Rezolute Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional
Rezolute Inc (RZLT) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Cantor Fitzgerald reiterates Overweight rating on Rezolute stock - Investing.com
What analysts say about Rezolute Inc. stockFree Bull & Bear Market Updates - jammulinksnews.com
What drives Rezolute Inc. stock priceOutstanding capital appreciation - Autocar Professional
Is Rezolute Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com
Rezolute to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Rare Disease Leader Rezolute Showcases Hypoglycemia Treatment Progress at BTIG Conference - Stock Titan
Rezolute posts patient demographics poster for Phase 3 sunRIZE study - Investing.com
Rezolute posts patient demographics poster for Phase 3 sunRIZE study By Investing.com - Investing.com South Africa
Rezolute Completes Enrollment for Phase 3 sunRIZE Study - TipRanks
Rezolute, Inc. shares rise 1.08% after-hours after registering a secondary offering of 1.3 million shares. - AInvest
Craig-Hallum Maintains Rezolute(RZLT.US) With Buy Rating - 富途牛牛
Craig-Hallum Reaffirms Their Buy Rating on Rezolute (RZLT) - The Globe and Mail
What makes Rezolute Inc. stock price move sharplyPredictable Return Stock Picks - Newser
Why Rezolute Inc. stock attracts strong analyst attentionInstant Stock Updates - Newser
How Rezolute Inc. stock performs during market volatilityFree Trading Strategy Suggestions - Newser
Rezolute Announces Presentation of Participant Baseline Data From Its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - 富途牛牛
Rezolute, Inc. Announces Late-Breaking Presentation of Phase 3 Study Data for Ersodetug at ENDO 2025 - Nasdaq
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - TradingView
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional investors must be pleased after a 11% gain last week that adds to Rezolute, Inc.'s (NASDAQ:RZLT) one-year returns - simplywall.st
Rezolute Inc: chief medical officer Roberts buys $10939 in shares - Investing.com
Rezolute CFO Evans buys $20,250 in company stock - Investing.com
Rezolute CFO Evans buys $20,250 in company stock By Investing.com - Investing.com India
Rezolute director Kim buys shares worth $3.99 million - Investing.com India
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Rezolute’s SWOT analysis: ersodetug trials boost stock amid clinical milestones - Investing.com India
Bank of America Corp DE Has $443,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Two Sigma Investments LP Sells 12,118 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Squarepoint Ops LLC Sells 3,980 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Millennium Management LLC Decreases Stake in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
69,724 Shares in Rezolute, Inc. (NASDAQ:RZLT) Bought by Ameriprise Financial Inc. - Defense World
Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77% - Yahoo Finance
BTIG maintains $15 target on Rezolute stock following trial update - Investing.com Australia
BTIG maintains $15 target on Rezolute stock following trial update By Investing.com - Investing.com India
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):